Association between the Prevalence of Somatic Mutations in PIK3CA Gene in Tumors and Clinical and Morphological Characteristics of Breast Cancer Patients


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The presence of activating somatic mutations in codons 542 and 545 of exon 9 (p.E542K c.1624G>A and p.E545K c.1633G>A) and in codon 1047 of exon 20 (p.H1047R c.3140A>G and p.H1047L c.3140A>T) of PIK3CA gene encoding catalytic p110α-subunit of phosphatidylinositol-3-kinase was studied in tumors of 473 breast cancer patients by multiplex allele-specific real-time PCR. Fifty-eight (12.3%) different mutations were found. An increase in the frequency of PIK3CA gene mutations with disease progression (from 2.4 to 28.7% with tumor progression from I-IIa to III-IV stage; p=0.0001) and a trend towards its increase in the tumors with unfavorable prognostic characteristics (high histological grade, triple negative phenotype) were demonstrated. The presence of the studied PIK3CA gene mutations in tumors significantly reduces relapse-free survival in the total group and in stage III cancer patients.

Sobre autores

M. Filipenko

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Autor responsável pela correspondência
Email: biochimia@yandex.ru
Rússia, Novosibirsk; Novosibirsk

N. Os’kina

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences

Email: biochimia@yandex.ru
Rússia, Novosibirsk

I. Oskorbin

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Email: biochimia@yandex.ru
Rússia, Novosibirsk; Novosibirsk

O. Mishukova

Institute of Chemical Biology and Fundamental Medicine, Siberian Division of the Russian Academy of Sciences; Novosibirsk National Research State University

Email: biochimia@yandex.ru
Rússia, Novosibirsk; Novosibirsk

L. Ovchinnikova

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Rússia, Moscow

E. Gershtein

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Rússia, Moscow

N. Kushlinskii

N. N. Blokhin Russian Cancer Research Center, Ministry of Health of the Russian Federation

Email: biochimia@yandex.ru
Rússia, Moscow


Declaração de direitos autorais © Springer Science+Business Media, LLC, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies